Aisling Capital’s ADMA Biologics ADMA Stock Holding History

Aisling Capital’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$16.1M	Hold	3,608,171	–	–	35.46%	2
2019 Q2	$14M	Hold	3,608,171	–	–	23.14%	2
2019 Q1	$13.7M	Hold	3,608,171	–	–	20.55%	2
2018 Q4	$8.62M	Hold	3,608,171	–	–	2.44%	3
2018 Q3	$22.4M	Hold	3,608,171	–	–	4.84%	3
2018 Q2	$16.3M	Hold	3,608,171	–	–	2.14%	5
2018 Q1	$16.6M	Hold	3,608,171	–	–	2.96%	5
2017 Q4	$11.6M	Hold	3,608,171	–	–	2.29%	6
2017 Q3	$11.1M	Hold	3,608,171	–	–	1.83%	6
2017 Q2	$13.3M	Hold	3,608,171	–	–	2.29%	6
2017 Q1	$17.6M	Hold	3,608,171	–	–	3.21%	7
2016 Q4	$18.5M	Hold	3,608,171	–	–	4.29%	7
2016 Q3	$26.2M	Hold	3,608,171	–	–	5.39%	8
2016 Q2	$21.5M	Hold	3,608,171	–	–	5.07%	7
2016 Q1	$29.2M	Hold	3,608,171	–	–	5.85%	6
2015 Q4	$29.1M	Hold	3,608,171	–	–	5.02%	8
2015 Q3	$30.2M	Hold	3,608,171	–	–	5.3%	6
2015 Q2	$33.4M	Hold	3,608,171	–	–	4.98%	8
2015 Q1	$35.4M	Hold	3,608,171	–	–	4.63%	8
2014 Q4	$40.3M	Buy	+3,608,171	New	+$41.3M	6.11%	9

Other funds holding ADMA

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aisling Capital's ADMA Position: Q3 2019 in Review

Aisling Capital held its ADMA Biologics (ADMA) position steady in Q3 2019 at 3,608,171 shares worth $16.1M. The position accounts for 35.46% of the portfolio, ranked #2.

Aisling Capital first reported a position in ADMA in Q4 2014 and has held it in 20 quarters since. The position peaked at $40.3M in Q4 2014. 72 funds tracked by Wall St. Rank hold ADMA as of Q3 2019.

Aisling Capital held 3,608,171 shares of ADMA Biologics worth $16.1M as of Q3 2019.
Aisling Capital left its ADMA Biologics share count unchanged in Q3 2019.
ADMA Biologics made up 35.46% of Aisling Capital's portfolio in Q3 2019, its #2 holding.
Aisling Capital first reported a position in ADMA Biologics in Q4 2014 and has held it in 20 quarters since.
Aisling Capital's ADMA Biologics position peaked at $40.3M in Q4 2014.
72 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2019.

Based on Aisling Capital's 13F filing for Q3 2019, filed 13 Nov 2019.